Trial Profile
Peg-IFN-alfa-2b/Ribavirin combination therapy for chronic hepatitis C patients: Effectiveness prediction by gene analysis and efficacy with Fluvastatin combination
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 12 May 2016
Price :
$35
*
At a glance
- Drugs Fluvastatin (Primary) ; Peginterferon alfa-2b (Primary) ; Ribavirin (Primary)
- Indications Hepatitis C
- Focus Pharmacogenomic; Therapeutic Use
- 21 Jun 2012 New trial record